Zentalis Pharmaceuticals (ZNTL) Accumulated Depreciation & Amortization (2019 - 2026)
Zentalis Pharmaceuticals' quarterly Accumulated Depreciation & Amortization came in at $151000.0 in Q1 2026, down 42.37% year-on-year from $262000.0 in Q1 2025, and down 79.57% quarter-over-quarter from $739000.0 in Q4 2025.
Zentalis Pharmaceuticals has reported Accumulated Depreciation & Amortization for 8 years, with the latest figure at $151000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Depreciation & Amortization fell 42.37% year-over-year to $151000.0; the trailing twelve-month figure through Mar 2026 stood at $151000.0 (down 42.37% YoY), and the FY2025 full-year result was $739000.0, down 43.15% from the prior year.
- Accumulated Depreciation & Amortization for Q1 2026 stood at $151000.0, down from $739000.0 in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $1.4 million in Q4 2022, with the low at $151000.0 in Q1 2026.
- Average Accumulated Depreciation & Amortization over 5 years is $572058.8, with a median of $348000.0 recorded in 2022.
- Year-over-year, Accumulated Depreciation & Amortization soared 335.44% in 2022 and plunged 51.07% in 2025.
- Tracing ZNTL's Accumulated Depreciation & Amortization over 5 years: stood at $1.4 million in 2022, then dropped by 0.79% to $1.4 million in 2023, then declined by 6.41% to $1.3 million in 2024, then slumped by 43.15% to $739000.0 in 2025, then plunged by 79.57% to $151000.0 in 2026.
- The last three Accumulated Depreciation & Amortization figures came in at $151000.0 (Q1 2026), $739000.0 (Q4 2025), and $582000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 151,000.00 |
| Mar 31, 2026 | 151,000.00 |
| Dec 31, 2025 | 739,000.00 |
| Dec 31, 2025 | 739,000.00 |
| Sep 30, 2025 | 582,000.00 |
| Sep 30, 2025 | 582,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Mar 31, 2025 | 262,000.00 |
| Mar 31, 2025 | 262,000.00 |
| Dec 31, 2024 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 972,000.00 |
| Sep 30, 2024 | 972,000.00 |
| Jun 30, 2024 | 327,000.00 |
| Jun 30, 2024 | 327,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Dec 31, 2023 | 1.39 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 348,000.00 |
| Sep 30, 2023 | 348,000.00 |
| Jun 30, 2023 | 344,000.00 |
| Jun 30, 2023 | 344,000.00 |
| Mar 31, 2023 | 360,000.00 |
| Mar 31, 2023 | 360,000.00 |
| Dec 31, 2022 | 1.40 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 375,000.00 |
| Sep 30, 2022 | 375,000.00 |
| Jun 30, 2022 | 348,000.00 |
| Jun 30, 2022 | 348,000.00 |
| Mar 31, 2022 | 344,000.00 |
| Mar 31, 2022 | 344,000.00 |
| Dec 31, 2021 | 544,000.00 |
| Dec 31, 2021 | 544,000.00 |
| Sep 30, 2021 | 335,000.00 |
| Sep 30, 2021 | 335,000.00 |
| Jun 30, 2021 | 119,000.00 |
| Jun 30, 2021 | 119,000.00 |
| Mar 31, 2021 | 79,000.00 |
| Mar 31, 2021 | 79,000.00 |
| Dec 31, 2020 | 160,000.00 |
| Dec 31, 2020 | 160,000.00 |
| Sep 30, 2020 | 127,000.00 |
| Sep 30, 2020 | 127,000.00 |
| Jun 30, 2020 | 76,000.00 |
| Jun 30, 2020 | 76,000.00 |
| Mar 31, 2020 | 38,000.00 |
| Mar 31, 2020 | 38,000.00 |
| Dec 31, 2019 | 111,000.00 |
| Dec 31, 2019 | 111,000.00 |
| Sep 30, 2019 | 70,000.00 |
| Sep 30, 2019 | 70,000.00 |
| Jun 30, 2019 | 45,000.00 |
| Jun 30, 2019 | 45,000.00 |
| Mar 31, 2019 | 21,000.00 |
| Mar 31, 2019 | 21,000.00 |